hold pt ozanimod refus file
downgrad celg hold buy lower pt
receipt refus file letter
fda ozanimod relaps form multipl sclerosi
fda determin nonclin clinic pharmacolog
section nda insuffici permit complet
review follow pipelin setback late ozanimod
central bull thesi re-acceler growth
franchis provid much need diversif away
myeloma given delay lower ozanimod peak
sale estim yatin suneja
tightrop decreas project reflect
gener headwind facil busi semga
greater drag expect uk asset sale
segment volum outlook gener slightli better
expect ebitda growth outlook impli lower
realiz across portfolio estim primarili semga
facil cush reduc pt
ebitda tristan richardson
 custom transit reiter buy terri tillman
brunswick corpor bc buy fire
cylind rais est brighter engin outlook
increas convict around bc marin engin unit
street-high ep next month specif
expect outboard momentum build near term
result new product/distribut gains/competit disrupt
base factor see potenti ep
upsid vs street expect next month
rais ep street maintain
 remain bullish follow solid print
guidanc modestli estimate/consensu think
like carri conservat continu like inher industri
tailwind see intensifi recognit virtu home
care view well posit potenti benefit
share gain unsettl competit backdrop
impress improv qualiti rate pristin balanc
sheet solid ton runway view
well posit reiter buy provid addit
detail post call david macdonald
retent bullish outlook esrx bolster follow
result mark solid core trend strong expect
bank region atlanta bank
activ could acceler
profit hotel last month
specialti financ guidanc point sustain growth
charg off
retent robust addit evicor acquisit
differenti servic offer drug trend look stellar
enterpris valu initi help underpin steadi adj
ebitda growth continu view esrx strateg posit
favor see attract growth opportun think visibl
cap favorit reiter buy provid addit details/
result mark decent volum across segment strong
full year guidanc ahead expect
review explor strateg altern still underway
amr sale still pend expect end
encourag underli trend continu like cap ex
light/strong gener busi model addit see
valu underli platform like amr proce provid
addit flexibl reiter buy rate provid
updat model addit detail follow
earn growth drive higher valuat base
investor dinner host cfo last even
increas confid strong annual ep growth
outlook compani period despit
strong move stock yesterday appear attract
price price-to-earnings multipl discount peer group base
estim ali agha
bank region atlanta bank
 activ could acceler view atlanta
bank market may see acceler merger activ
recent announc pend sale billion
asset atlanta-bas hamilton state bancshar ameri bank
like catalyst acceler activ believ
digest bank headquart atlanta
million deposit market see page
brunswick corpor bc buy fire
cylind rais est brighter engin outlook
increas convict around bc marin engin unit
street-high ep next month specif
expect outboard momentum build near term
result new product/distribut gains/competit disrupt
base factor see potenti ep
upsid vs street expect next month
rais ep street maintain
page
ebitda estim go
ep estim go
price target goe
price target base multipl
unchang blend sotp ebitda estim
us sidelin beat outlook
prove disappoint annual guidanc assum acceler
domest trend wholesal retail think
add risk stori improv need occur
compani simultan work scale lower margin busi
new growth initi rais estim
reflect lower tax rate partial off-set higher sg
result significantli lower om prior outlook
reiter hold pt assum
forward pe in-lin histor averag pamela quintiliano
frustrat follow result guidanc
lower ebitda estim
respect
guidanc disappoint expect stock open
tomorrow believ see upsid number
expans also still view compani
attract asset larger multin maintain
buy rate price target equat
ebitda estim line high growth peer
print back retail acceler michael swartz
quarter anoth initi guid in-line
maintain estim hold rate pt follow
anoth strong quarter in-line guidanc
continu like stori long-term share trade
ntm ep would look better entri point michael
hold drama continu tomorrow night pt
goe ep goe
tax reform revenu recognit rule chang
chang licens agreement impact number
introduc ebitda ep
price target goe roll forward
ebitda target target multipl blend sotp
unchang patrick schole
inc buy
wood green shoot emerg rais pt
page
rais ebitda slightli pt
work progress came away increment
posit busi believ revenue/ebitda growth
could final reemerg buy michael swartz
electr power util
earn growth drive higher valuat base
investor dinner host cfo last even
increas confid strong annual ep growth
outlook compani period despit
strong move stock yesterday appear attract
price price-to-earnings multipl discount peer group base
estim ali agha
estim rais estim base updat cost
interest expens assumpt reduc
estim increas estim ali agha
tightrop decreas project reflect
gener headwind facil busi semga
greater drag expect uk asset sale
segment volum outlook gener slightli better
expect ebitda growth outlook impli lower
realiz across portfolio estim primarili semga
facil cush reduc pt
ebitda tristan richardson
subtl meaning yesterday afternoon announc
in-lin guid product oilier rais exit-r
guidanc announc two transact increas liquid
see note look growth back-half weight
take-away constraint wattenberg allevi
product move move
continu see mewbourn subsequ plant
key near-term catalyst growth feel regulatori
overhang exagger host call topic
co polit expert et ask sale dial-in
page
chang guidanc despit solid merg well
number oper issu occur past week
caus eagl ford delawar product impact howev
unnerv mani problem spring
take solac compani appear conserv
much upcom guidanc includ efficiencies/
recent improv well result w/ potenti result futur posit
type curv revis declin leverag forecast
carrizo stock trade earn estim
believ anyth low onshor growth
bank region atlanta bank
 activ could acceler view atlanta
bank market may see acceler merger activ
recent announc pend sale billion
asset atlanta-bas hamilton state bancshar ameri bank
like catalyst acceler activ believ
digest bank headquart atlanta
million deposit market see page
 tank pump ebitda expans maintain
hold rate follow investor day new
york manag laid framework recent
invest help fuel continu growth within core
point tank divis appear
hit inflect point record first year-over-year
growth seven quarter pt equat
premium equip rental stock
reflect strong market posit growth prospect
collect purchas ep rais
estim mainli reflect tax reform
establish estim quarter
better expect top- bottom-lin despit
ramp collect capac sustain conserv treatment
newer paper outlook appear particularli favor
page
light heavi purchas prospect improv
collector product turn benefit portfolio yield
reiter buy rate price target next
model dividend increas announc increas
quarterli cash dividend per share per
share quarterli cash dividend payabl april
stockhold record march repres
consecut cash dividend paid first mid-west sinc
incept updat model reflect
price higher assum loss cut
estim forecast
goe driven expect higher accid year
loss ratio vs previous lower
favor develop point vs prior model
price target earn
modest premium specialti group averag figur
acceler top-line environ reiter buy
rate maintain estim follow result
shift earn model slightli favor current accid year
profit rather reserv gain assum point
vs previous believ good shape
take advantag improv new busi condit
excess surplu think price-to-earn
valuat particularli next year number look attract
figur new price target prior assum
hold multipl mid-twenti appreci
specialti financ guidanc point sustain growth
charg off mark hugh
hold pt ozanimod refus file
downgrad celg hold buy lower pt
receipt refus file letter
fda ozanimod relaps form multipl sclerosi
fda determin nonclin clinic pharmacolog
section nda insuffici permit complet
review follow pipelin setback late ozanimod
central bull thesi re-acceler growth
franchis provid much need diversif away
myeloma given delay lower ozanimod peak
sale estim yatin suneja
page
 remain bullish follow solid print
guidanc modestli estimate/consensu think
like carri conservat continu like inher industri
tailwind see intensifi recognit virtu home
care view well posit potenti benefit
share gain unsettl competit backdrop
impress improv qualiti rate pristin balanc
sheet solid ton runway view
well posit reiter buy provid addit
detail post call david macdonald
retent bullish outlook esrx bolster follow
result mark solid core trend strong expect
retent robust addit evicor acquisit
differenti servic offer drug trend look stellar
enterpris valu initi help underpin steadi adj
ebitda growth continu view esrx strateg posit
favor see attract growth opportun think visibl
cap favorit reiter buy provid addit details/
result mark decent volum across segment strong
full year guidanc ahead expect
review explor strateg altern still underway
amr sale still pend expect end
encourag underli trend continu like cap ex
light/strong gener busi model addit see
valu underli platform like amr proce provid
addit flexibl reiter buy rate provid
updat model addit detail follow
guidanc realign street focu expans data
 zejula parp inhibitor sale
street togeth initi guidanc zejula
mostli in-line estim
like see increas competit pressur
believ stock attract posit follow reset
revenu expect potenti posit news flow
market expans reiter buy reduc
pt rebal core revenu
improv continu portfolio ration help
lower debt addit guidanc in-lin bracket
consensu howev on-going elev cost oper
challeng volum environ modest expect
suggest addit work given heavi debt load
page
gener remain critic maintain hold provid
addit details/upd model post call david
growth midpt john bori
call bump estim rais maintain
hold rate follow solid result mark posit volum
trend headway hand initi improv qualiti
spur growth improv cost manag earli
process conif sale underway continu
look opportun improv overal portfolio flow
saw improv guidanc encourag
reason optim surgic volum remain challeng
critic execut paramount maintain hold
rais pt ebitda
valid continu earn help reiter
seri catalyst throughout
expect data nudg back
updat flotetuzumab aml data could
continu defin aml play
develop highli function bival antibodi also expect
data enoblituzumab combo trial nudg
back could valid target
would buyer ahead data reiter buy
underscor strength commerci opportun lefamulin
cabp yesterday kol call emerg medicin
specialist discuss lefamulin clinic data commerci
opportun support invest thesi lefamulin could
promis new treatment community-acquir bacteri
unmet medic need cabp suggest phase
leap iv oral data highli encourag top-lin data
second phase studi leap oral expect
encourag insight gain
reiter buy rate pt nbrv share edward
attract head read-out landmark cv outcom
studi maintain vascepa sale
yoy street amrn
widen lp vs street
initi media campaign increas
vascepa awar potenti cv benefit reduce-it
likelihood show cv benefit amrn expect
mace reduce-it achiev top-line data
page
amrn risk/reward appear favor bull/bear
impli reiter base dcf
posit roll remain bullish
follow anoth solid print mark strong core trend
on-going cost manag robust encoura growth
opportun sever front continu see
capabl competit advantag view innov
partnership share gain opportun risk-shar
enhanc post-acut manag cf robust
pipelin full expect capit deploy continue/lik ramp
hh/hospic remain area focu reiter buy rate
ebitda price target david macdonald
earn call remain bullish fm tie solid core
trend robust cash flow on-going cost save progress
global effici program see
hurdl pharmaci na rev/tx fx flattish/slightli
volum remain strong care coordin trend robust
nxstage acquisit remain track close lastli
gener robust balanc sheet clean leav
fm well posit capit deploy opportun
reiter buy rate pt ebitda
today verona announc result provid corpor
mainten data expect earli base
result believ management could move rapidli toward
pivot program copd mainten addit success
advanc drug directli phase develop meanwhil
phase iia data second indic cystic fibrosi cf
expect march inform futur develop
reiter buy npv-deriv pt yatin suneja
accept eravacyclin nda submiss file edward nash
broaden franchis nda set
submiss brexanolon nda file postpartum depress
track prepar potenti
commerci launch outlin increas
pt ad moder patient
brexanolon project believ anoth
catalyst-rich year multipl trial initi
readout expect includ top-lin data expand
phase ii studi posit could
page
faster path registr remain bullish share
revis adjust ep estim
adjust ep estim increas slightli
maintain price target repres
adjust ebitda estim
ebitda estim averag roll four-quart multipl
stock one standard deviat
growth believ particularli impress quarter
given exceed expect despit margin drag
distribut unit continu backlog home construct
project coupl limit labor help smooth project
work instal stock remain weak uptick
interest rate rais question futur home buy activ
believ stock group remain laggard
question solv believ rate move
enough significantli dampen demand thu remain buy
 result slightli ahead refinanc later could
catalyst result came modestli
outperform group day regardless stock
stuck low valuat time limit
liquid simpli forgotten view compani
notabl refinanc opportun would pare
divestitur non-cor mi busi jump start
stock also believ averag sg gain could
rais interest remain buy rate modest valuat
note someth dramat need occur break name
penalti box sinc ipo keith
co corpor buy solid result
guidanc rais keep momentum go michael ciarmoli
 focu ag recoveri specialti mix improv
 pah share rose solid releas
earn slightli beat expect pah
rais ebitda guidanc rang y/
bracket consensu believ growth
line pah long-term target high single-digit ebitda
growth achiev headwind ag condit fx
page
headwind raw materi cost pressur larg abat
equiti issuanc pend ag separ like
shrink leverag conglomer discount current valuat
ebitda reiter buy jame sheehan
inflat limit margin gain lumber continu compress
result fall stock much differ
homebuilder-link peer anoth weak day lumber inflat
pressur margin anticip
thu flatten metric could provid substanti lift
stori current valuat recess type multipl
name struggl combin lumber sudden ceo
chang slightli higher rate believ cycl
keep buy rate stock view get releas
attract entri point keith hugh
firm disast recoveri move slowli reiter
buy rate pt faster expect sale growth
high-singl digit increas fed civil spend tie
two-year budget deal disast recoveri rfp slower
develop expect vs previous
enthusiasm residenti recoveri opportun remain
high commerci busi rose strength energi
market small int sale rose increas adj
ep estim
lower tax establish quarterli dividend
conservat embed cautiou outlook buy adjust
pt reduc adjust ep
estim estim
given cautiou outlook healthcar market
demand encourag strengthen
healthcar market demand reiter buy rate
hold remain hold reiter pt
ebitda view balanc risk/reward owe
roughli revenue exposur mortgag volum protract vendor
diversif caus share loss vsg view
unpredict interest rate mortgag volum environ
cap valuat also believ factor limit upsid
model creat risk compani margin
target new revenu ebitda est
prior
page
street
reiter hold acknowledg squar technolog
valu proposit reson broad swath smb
evidenc impress organ revenue growth
industri averag rais pt ebitda
said believ grow portion growth
fuel inher cyclic offer capit
creat increment risk particularli current valuat
opinion revenue ebitda est
littl chang street
 andrew jeffrey
highlight creativ user premium rent best space
yesterday attend cxp tour midtown south asset
new york includ park avenu south west
street west street leas activ
healthi renov properti demand
notabl increment news may east street
expect sell price low- million rang
cap rate million suggest
articl deal partial due higher interest rate
make adjust model michael
profit hotel last month new seri
introduc decemb analyz oper level
metric hundr upper-ti full servic hotel data
sourc hotstat monthli revpar result well
dissemin understood thank str actual hotel
oper profit past month far less known
believ report help dispers fog investor
regard hotel-level profit hotel reit well
c-corp own hotel profit trend intra-quart
cost trend impact margin futur period patrick
appl guid in-lin consensu patrick schole
 acq focu small high-end hotel creativ
ebitda goe affo/
share goe introduc
ebitda estim affo/shar estim
price target unchang base multipl
unchang in-lin portfolio qualiti ebitda
page
 custom transit reiter buy terri tillman
progress strateg shift reaffirm buy bkng
success deliv strong growth improv roi
perform ad spend attest good execut amidst
focu strateg prioriti higher ad effici sustain lt
growth importantli perform mgt commentari
suggest fundament on-line travel remain intact
help allevi fear structur slowdown view
room night guid conserv expect see growth
trend improv compani anniversari tough comp
begin realiz greater benefit brand advertis push
reset expect strong fundament set stage
out-performance report solid view
carrier consolidation-driven churn india higher straight-
line expens recently-sign mla agreement us
neg impact guidanc rel consensu
expect importantli view headwind
known outlook set believ pois
deliv beat-and-rais result acceler us
intern ex-india leas activ believ
well posit beyond gain momentum
india normal reiter buy target
 greg miller
microsemi corpor mscc buy
page
feb corpor group dinner cfo head ir new york
march unisi corpor ndr cfo vice-president ir new york new
mrch syntel inc synt ndr president/ceo vice-president financ head ir boston new
march wn hold ltd wn ndr corpor svp financ head ir mid-west
march group meet legacytexa group ltxb variou
march ndr ceo futurestep svp financ treasuri tax ir new york new
march coreciv inc ndr president/ceo manag director ir boston toronto
march central garden pet co ndr president/ceo vice-president ir/commun new york
march corp ndr ceo vice-president ir atlanta chicago
march ndr ceo/presid director ir mid-atlant
page
april nomad food limit nomd ndr ceo head ir new york
march texa bank field variou management team gnbc pb dalla
march group function enterpris connect orlando zoom orlando new
march shoptalk meet strh la vega
feb estimate conf call kol discuss nabriva lefamulin anticip result
march estimate conf call plc nbrv
march estimate conf call inc
page
march youssef squali nave khan internet/digit media mid-atlant
march jennif demba michael young bank dalla
march ki bin michael lewi greg miller reit boston
page
issu research report suntrust robinson humphrey inc analyst name report herebi certifi
recommend opinion express accur reflect research analyst person view
subject secur compani discuss herein part research analyst compens directli
indirectli relat specif recommend view express report
